Indian generics makers claim victory in anaemia drug patent feud

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Indian generics makers claim victory in anaemia drug patent feud

Generic drug.jpg

The Delhi High Court said third parties who use different processes to make a patented product can’t be restricted if the plaintiff’s registration covers a product-by-process patent

The Delhi High Court has denied Swedish drug maker Vifor Pharma’s application to prevent four Indian companies from launching generic versions of its iron-deficiency anaemia drug.

Justice Jyoti Singh ruled on Monday, July 24, that a drug patent only covering process claims could not be used to restrict third parties who derived the same compound through different methods.

The decision marks the first time the court has delved into what constitutes a product-by-process claim.

Vifor had claimed that its patent covered a product featuring ‘ferric carboxymaltose’ (FCM) as well as a process to prepare it. The Swedish drugmaker sells its FCM products in India under the brand names Ferinject, Injectafer and Revofer.

The company argued that its patent was actually for a product even though it described a process. Therefore, irrespective of the defendants’ process, any FCM production would infringe its patent.

However, defendants Dr Reddy’s Laboratories, MSN Laboratories, Corona Remedies, and Virchow Biotech claimed that Vifor’s invention was limited to a product obtained through the specific process mentioned in its patent application.

The court sided with the defendants and found that Vifor’s claims covered a product-by-process patent. It said the process terms were limitations to, and not additional features of, the rights granted to the company.

The court held that Corona and Virchow's products were different from Vifor’s and not infringing. It also found that the processes claimed by Dr Reddy’s and MSN were outside the scope of Vifor’s process and so were also non-infringing.

Corona had already placed its product on the market in 2020. This week’s decision paves the way for the other three companies to launch their products before Vifor’s patent expires in October.

more from across site and SHARED ros bottom lb

More from across our site

Sources explain why return-to-office mandates could hamper efficiency at the USPTO
The Unified Patent Court surpassing 700 cases and a row between Apple and PanOptis were among the top talking points this week
Partners at four firms explain how they help clients join in the hype around the big game without attracting the NFL’s wrath
We discuss how law firms are using AI, whether remote working has resulted in cost-savings, and what corporate counsel want from their advisers when it comes to DEI
Matthew Yeates, managing director at Integrated IP, discusses its acquisition of Clark IP and reveals further expansion plans
Paul Lee discusses moving from venture capital to IP, why lawyers are becoming more receptive to tech, and why he starts his day with a cold plunge
Barbara Lawton, a counsellor and mental health trainer at wellbeing charity Jonathan’s Voice, outlines tips for engaging with vulnerable people
New partner Amir Ghavi, who will help launch the group, says he expects more lateral hires in the coming weeks
Counsel at three firms reveal the tools they’re using to generate patent invalidity claim charts and why they’re making investments in the technology
Eric Lee says the firm’s thought leadership on artificial intelligence convinced him to move
Gift this article